Publications by authors named "R Chanana"
Article Synopsis
- High-grade B-cell non-Hodgkin lymphomas (NHLs) are more prevalent in patients with HIV, and this study reflects on the treatment outcomes of such patients treated with a specific chemotherapy regimen called DA-EPOCH(+/-R) from 2011 to 2015.
- The analysis included 40 patients with various types of B-cell NHL, and a notable 82.5% had a 5-year overall survival rate, indicating the regimen's effectiveness.
- While most patients experienced significant side effects, such as febrile neutropenia and mucositis, the treatment remains a viable option even for those with serious health challenges related to HIV.
Introduction: Primary Mediastinal B cell lymphoma (PMBCL) is a biologically and clinically distinct subset of diffuse large B cell lymphoma. We analysed the outcomes of our cohort of PMBCL patients treated with Dose adjusted (DA)-R-EPOCH regimen.
Patients And Methods: This is a retrospective analysis of consecutive PMBCL patients who received chemotherapy consisting of DA-R-EPOCH with filgrastim support.
Purpose: Infections remain a major challenge in the treatment of acute myeloid leukemia (AML). Induction-related mortality reported in the literature is approximately < 5% in clinical trials. However, the real-world scenario is different, especially in developing countries, given the high incidence of multidrug-resistant (MDR) organisms, high incidence of fungal pneumonia at baseline, and significant delay before initiation of chemotherapy.
View Article and Find Full Text PDFBackground: The management of T-lymphoblastic lymphoma (T-LBL) in adults poses uncertainties, including optimal chemotherapy regimen, need for radiotherapy, and the benefit of stem cell transplant. This retrospective case series investigated the efficacy of the pediatric BFM-90 regimen in adult patients and evaluated the role of early response assessment by positron emission tomography with computed tomography (PET-CT) in predicting outcomes.
Methods: Patients aged 15 years or older with T-LBL diagnosed at Tata Memorial Hospital, Mumbai, India were given chemotherapy according to the European BFM-90 protocol (n = 38).
ROS1 rearrangement acts as a driver mutation in 1-2% of NSCLC. Crizotinib is approved in this situation both in treatment naïve and pre-treated patients. Here we report our experience with crizotinib in patients with advanced NSCLC harbouring ROS1 rearrangement.
View Article and Find Full Text PDF